Lymphoma, Extranodal NK-T-Cell
Information
- Disease name
- Lymphoma, Extranodal NK-T-Cell
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03049449 | Completed | Phase 1 | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | March 17, 2017 | January 26, 2022 |
| NCT00069238 | Completed | Phase 2 | Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas | September 19, 2003 | March 17, 2021 |
| NCT04417166 | Recruiting | Phase 2 | Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma | February 11, 2022 | December 2026 |
| NCT02859402 | Recruiting | Phase 2 | Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas | December 2016 | December 2027 |
| NCT03646422 | Recruiting | AEDV Registry of Primary Cutaneous Lymphoma | September 1, 2016 | January 1, 2025 | |
| NCT02533323 | Terminated | Phase 2 | P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens | January 2012 | January 2017 |
| NCT01948180 | Terminated | Phase 2 | Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma | September 2014 | September 7, 2018 |
| NCT02359162 | Terminated | Phase 3 | Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage | May 2015 | June 2017 |
| NCT02080234 | Unknown status | Phase 2 | Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL | March 2014 | March 2017 |
| NCT03051542 | Unknown status | N/A | Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma | March 1, 2017 | December 31, 2020 |
| NCT03051555 | Unknown status | N/A | 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma | March 1, 2017 | December 31, 2020 |
| NCT03154918 | Unknown status | Phase 2 | GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma | June 1, 2017 | March 30, 2021 |
| NCT03439501 | Unknown status | Phase 2 | Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] | January 16, 2018 | March 30, 2022 |
| NCT01933282 | Unknown status | Phase 2 | MESA Treatment for NK/T Cell Lymphoma | January 2013 | January 2015 |
| NCT02878278 | Unknown status | Phase 2 | Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation | September 2016 | September 2019 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D054391